Drugs / huCART-meso cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05623488 | Feb 2023 → Apr 2025 | breast cancer | University of Pennsylvania | Terminated | No outcome recorded |
| Phase 1 | NCT03323944 | Sep 2017 → Feb 2025 | malignant pancreatic neoplasm | University of Pennsylvania | Terminated | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT03054298 Comparator | Apr 2017 → Nov 2023 | fallopian tube cancer, lung adenocarcinoma, ovarian cancer, peritoneal carcinoma +2 | University of Pennsylvania | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | huCART-meso cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03054298 ↗ |
| Modality | Cell therapy | “CAR T Cells in Mesothelin Expressing Cancers” NCT03054298 ↗ |
| Route | Intravenous | “via IV infusion” NCT03054298 ↗ |